The proposed merger of Sequent Scientific and Viyash Life Sciences, backed by Carlyle, has received overwhelming shareholder support. This ₹8,000-crore merger aims to create a global entity, combining Sequent's animal health focus with Viyash's human health expertise. Hari Babu Bodepudi, the (...)
Site référencé: The Economic Times
The Economic Times
The Golden Thumb Rule | For Gen Z investors, time in the market beats timing the market, says Kaustubh Belapurkar
6/09/2025
IPO Calendar : Urban Company to lead Rs 2,700 crore worth offers in a busy week
6/09/2025
Wall Street’s wealth engine powers through job-market anxiety
6/09/2025
Hedge funds jump into bullish oil bets on tight supply signals
6/09/2025
Will Indian banks meet the SWIFT ISO 20022 implementation deadline ?
6/09/2025
Will global cues and Fed rate cut hopes fuel a market recovery next week ?
6/09/2025
